PTGS2 and neoplasm: 11ßHSD2 inhibition will not produce immunosuppression or other systemic side effects of conventional glucocorticoid therapy; 4) In addition to inhibiting the COX-2 pathway, increased tumor active GCs also inhibit lung tumorigenesis through inhibiting the ERK and mTOR signaling pathways as well as induction of G1 cell cycle arrest [51].